scholarly journals Sclerostin Antibody–Induced Changes in Bone Mass Are Site Specific in Developing Crania

2019 ◽  
Vol 34 (12) ◽  
pp. 2301-2310 ◽  
Author(s):  
Amanda L Scheiber ◽  
David K Barton ◽  
Basma M Khoury ◽  
Joan C Marini ◽  
Donald L Swiderski ◽  
...  
Keyword(s):  
Bone Mass ◽  
Site Specific ◽  
Induced Changes ◽  
Sclerostin Antibody

scholarly journals Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

2009 ◽  
Vol 24 (4) ◽  
pp. 578-588 ◽  
Author(s):  
Xiaodong Li ◽  
Michael S Ominsky ◽  
Kelly S Warmington ◽  
Sean Morony ◽  
Jianhua Gong ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Postmenopausal Osteoporosis ◽  
Bone Strength ◽  
Rat Model ◽  
Antibody Treatment ◽  
Sclerostin Antibody

scholarly journals Deletion of Rptor in pre‐osteoblasts reveals a role for the mTORC1 complex in dietary‐induced changes to bone mass and glucose homeostasis in female mice

JBMR Plus ◽  
2021 ◽  
Author(s):  
Pawanrat Tangseefa ◽  
Sally K. Martin ◽  
Agnieszka Arthur ◽  
Vasilios Panagopoulos ◽  
Amanda J. Page ◽  
...  
Keyword(s):  
Bone Mass ◽  
Glucose Homeostasis ◽  
Female Mice ◽  
Induced Changes

Low Level of Serum Sclerostin in Adult Patients with Tumor-induced Osteomalacia Comparing with X-linked Hypophosphatemia

2021 ◽  
Author(s):  
Xiaolin Ni ◽  
Qi Zhang ◽  
Xiang Li ◽  
Qianqian Pang ◽  
Yiyi Gong ◽  
...  
Keyword(s):  
Bone Mass ◽  
Cross Sectional Study ◽  
Healthy Controls ◽  
Cross Sectional ◽  
Significant Difference ◽  
Healthy Control ◽  
Premenopausal Patients ◽  
Male Patients ◽  
Sclerostin Level ◽  
Sclerostin Antibody

Abstract Context Sclerostin is an inhibitor of Wnt-β-catenin signaling to regulate bone formation. Circulating sclerostin levels were reported to be elevated in patients with X-linked hypophosphatemia (XLH), and sclerostin antibody (Scl-Ab) has been shown to increase bone mass and normalize circulating phosphate levels in Hyp mice. However, circulating sclerostin level in acquired hypophosphatemic patients with tumor-induced osteomalacia (TIO) remains rare reported. Objectives This study was designed to evaluate serum sclerostin levels in TIO patients comparing them with age-, sex- matched healthy controls and XLH patients, and analyze correlation of circulating sclerostin with BMD and laboratory parameters. Design, Setting and Participants 190 individuals including 83 adult TIO patients, 83 adult healthy controls and 24 adult XLH patients were enrolled in this cross-sectional study. Main outcome measures Serum sclerostin levels were determined in TIO patients, healthy controls and XLH patients. Results TIO patients (43 male and 40 female) aged 44.3 ± 8.7 (mean ± SD) years had lower levels of circulating sclerostin than healthy controls (94.2 ± 45.8 vs 108.4 ± 42.3 pg/mL, p = 0.01) with adjustment for age, gender, BMI and diabetes rate. Sclerostin levels were positively associated with age (r = 0.238, p = 0.030). Male patients had higher sclerostin level than female patients (104.7 ± 47.3 vs 83.0 ± 41.8 pg/mL, p = 0.014) and postmenopausal patients had higher tendency of sclerostin level than premenopausal patients (98.4 ± 48.8 vs 71.6 ± 32.3 ng/ml, p = 0.05). Sclerostin levels were positively associated with BMD of L1-4 (r = 0.255, p = 0.028), femoral neck (r = 0.242, p = 0.039) and serum calcium (r = 0.231, p = 0.043). TIO subgroup patients (n=24, 35.9 ± 7.3 years old) comparing with age-, sex-matched adult XLH patients and healthy controls revealed significant difference of sclerostin levels (XLH, TIO and healthy control were 132.0 ± 68.8, 68.4 ± 31.3 and 98.6 ± 41.1 pg/mL, respectively, p < 0.001). Conclusions Circulating sclerostin levels were decreased in TIO patients but increased in XLH patients, which might be result of histological abnormality and bone mass.

Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice

Bone ◽  
2021 ◽  
pp. 116201
Author(s):  
Kelsey A. Carpenter ◽  
Reid Davison ◽  
Shruti Shakthivel ◽  
Kyle D. Anderson ◽  
Frank C. Ko ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Phosphate Metabolism ◽  
Sclerostin Antibody

scholarly journals Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model

2018 ◽  
Vol 33 (7) ◽  
pp. 1272-1282 ◽  
Author(s):  
Diana Olvera ◽  
Rachel Stolzenfeld ◽  
Joan C Marini ◽  
Michelle S Caird ◽  
Kenneth M Kozloff
Keyword(s):  
Mouse Model ◽  
Bone Mass ◽  
Osteogenesis Imperfecta ◽  
Trabecular Bone ◽  
Low Dose ◽  
Trabecular Bone Mass ◽  
Sclerostin Antibody

Exercise effects on bone mass in postmenopausal women are site-specific and load-dependent

2009 ◽  
Vol 11 (2) ◽  
pp. 218-225 ◽  
Author(s):  
Deborah Kerr ◽  
Alan Morton ◽  
Ian Dick ◽  
Richard Prince
Keyword(s):  
Bone Mass ◽  
Postmenopausal Women ◽  
Site Specific

OP0044 The effects of multiple doses of sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 67.3-68
Author(s):  
D. Padhi ◽  
M. Allison ◽  
A.J. Kivitz ◽  
M.J. Gutierrez ◽  
B. Stouch ◽  
...  
Keyword(s):  
Bone Mass ◽  
Postmenopausal Women ◽  
Low Bone Mass ◽  
Healthy Men ◽  
Multiple Doses ◽  
Sclerostin Antibody

scholarly journals O PRIRODE ZONOSPETsIFIChNOSTI REAKTsIY SKELETA ChELOVEKA V USLOVIYaKh NEVESOMOSTI»

2011 ◽  
Vol 14 (3) ◽  
pp. 3-6
Author(s):  
V. S. Oganov ◽  
I. A. Skripnikova ◽  
V. E. Novikov ◽  
A. V. BAKULIN ◽  
O. E. KABITsKAYa ◽  
...  
Keyword(s):  
Bone Mass ◽  
Individual Variability ◽  
Homo Erectus ◽  
Site Specific ◽  
Local Bone ◽  
Long Duration ◽  
Genes Expression ◽  
Different Types ◽  
History Of ◽  
The Individual

Densitometry of cosmonauts following long duration missions revealed different types of site specific changers of human skeleton. So, theoretically, the expected a decrease in bone mass according with gravity vector reflected the local specificity of bone genes expression connected with the mechanical history of Homo erectus evolution. High individual variability of bone mass changes may be a manifestation of genetic polymorphism. We show the individual stability of bone mass changes at different sites of skeleton after repetitive spaceflights. This phenomenon may be considered as an illustration of phenotypical characteristics of local bone metabolism in the form of specific for this locus spatial structure of non-collagenic proteins distribution.

Sign in / Sign up

Export Citation Format

Share Document